• NewAmsterdam Pharma Company NV NAMS.OQ reported a quarterly adjusted loss of 15 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -41 cents. The mean expectation of thirteen analysts for the quarter was for a loss of 49 cents per share. Wall Street expected results to range from -63 cents to -30 cents per share.

• Revenue rose 740.1% to $19.15 million from a year ago; analysts expected $1.60 million.

• NewAmsterdam Pharma Company NV's reported EPS for the quarter was a loss of 15 cents​.

• The company reported a quarterly loss of $17.36 million.

• NewAmsterdam Pharma Company NV shares had risen by 20.0% this quarter and lost 15.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 5.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for NewAmsterdam Pharma Company NV is $43.00, about 49.5% above its last closing price of $21.73

This summary was machine generated from LSEG data August 6 at 12:45 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)